

Original Article

Endocrinol Metab 2013;28:214-220 http://dx.doi.org/10.3803/EnM.2013.28.3.214 pISSN 2093-596X · eISSN 2093-5978

Herpes Virus Entry Mediator Signaling in the Brain Is Imperative in Acute Inflammation-Induced Anorexia and Body Weight Loss

Kwang Kon Kim, Sung Ho Jin, Byung Ju Lee

Department of Biological Sciences, University of Ulsan College of Natural Sciences, Ulsan, Korea

Background: Reduced appetite and body weight loss are typical symptoms of inflammatory diseases. A number of inflammatory stimuli are responsible for the imbalance in energy homeostasis, leading to metabolic disorders. The herpes virus entry mediator (HVEM) protein plays an important role in the development of various inflammatory diseases, such as intestinal inflammation and diet-induced obesity. However, the role of HVEM in the brain is largely unknown. This study aims to investigate whether HVEM signaling in the brain is involved in inflammation-induced anorexia and body weight loss.

Methods: Food intake and body weight were measured at 24 hours after intraperitoneal injection of lipopolysaccharide (LPS) or intracerebroventricular injection of recombinant mouse LIGHT (also called tumor necrosis factor receptor superfamily 14, TNFSF14), an HVEM ligand, into 8- to 10-week-old male C57BL/6 mice and mice lacking HVEM expression (HVEM-/-). We also assessed LPS-induced change in hypothalamic expression of HVEM using immunohistochemistry.

Results: Administration of LPS significantly reduced food intake and body weight, and moreover, increased expression of HVEM in the hypothalamic arcuate nucleus. However, LPS induced only minor decreases in food intake and body weight in HVEM-/mice. Administration of LIGHT into the brain was very effective at decreasing food intake and body weight in wild-type mice, but was less effective in HVEM-/- mice.

Conclusion: Activation of brain HVEM signaling is responsible for inflammation-induced anorexia and body weight loss.

Keywords: Brain; Inflammation; Receptors, tumor necrosis factor; Anorexia

INTRODUCTION

In inflammatory conditions, a syndrome referred to as the sickness response occurs in a number of different ways. Reduced appetite and body weight loss are typical symptoms of inflammatory diseases [1-3]. Anorexia, a symptom of decreased appetite, is associated with a wide range of acute and chronic pathological conditions which are characterized by an in-

flammatory state, such as bacterial or parasitic infection, cancer or chronic inflammatory bowel disease [4,5]. This sickness-related anorexia negatively affects recovery and treatment success with a decreased quality of life. A prolonged reduction in food intake will deplete body fat and protein reserves, resulting in malnutrition, impaired host immune functions, and increased morbidity and mortality [6]. Therefore, elucidating the mechanism of infection-associated anorexia

Received: 26 April 2013, Accepted: 19 July 2013 Corresponding author: Byung Ju Lee

Department of Biological Sciences, University of Ulsan College of Natural Sciences, University of Ulsan, 93 Daehak-ro, Nam-gu, Ulsan 680-749, Korea **Tel:** +82-52-259-2351, **Fax:** +82-52-259-1694, **E-mail:** bjlee@ulsan.ac.kr

Copyright © 2013 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

and weight loss is essential to improve patient quality of life.

Proinflammatory cytokines play critical roles in the etiology of disease- and infection-related anorexia [7-9]. The brain is an important target for proinflammatory cytokines that affect the neuronal circuits controlling food intake and energy homeostasis [10,11]. Inflammation in the brain results in a profound state of negative energy balance that is an adaptive response to infection [12,13]. Administration of bacterial endotoxins, such as lipopolysaccharide (LPS), has been demonstrated to induce sickness response behavior in laboratory animals by inducing acute inflammation in the brain as well as the peripheral organs [14,15].

Members of the tumor necrosis factor receptor superfamily (TNFRSF) play a key role in regulating the immune response to infection [16]. Herpes virus entry mediator (HVEM, also called as TNFRSF14) is a membrane receptor that binds several ligands and mediates costimulatory pathways, predominantly through its interaction with LIGHT (also called as TN-FSF14). HVEM also mediates coinhibitory effects, predominantly by interacting with immunoglobulin (Ig) superfamily members, B- and T-lymphocyte attenuator, or CD160 [17]. Therefore, HVEM can be considered a molecular switch for various activating or inhibitory functions [18,19].

HVEM activates the nuclear factor (NF)-κB pathway, leading to the induction of proinflammatory genes [20]. Recently, several studies have reported that HVEM-mediated stimulatory signals are essential for promoting proinflammatory cytokine production and intestinal pathology [21,22] and are important in hepatic inflammatory disease [23]. Moreover, HVEM deficiency attenuates the inflammatory responses of adipose tissue and glucose intolerance in diet-induced obesity [24]. Collectively, these data implicate that HVEM plays a proinflammatory role in peripheral tissues. However, little is known about its function in the brain.

In this study, we assessed changes in food intake and body weight after intraperitoneal (IP) administration of LPS or intracerebroventricular (ICV) injection of LIGHT and demonstrated that HVEM deficiency ameliorated inflammation-induced anorexia and weight loss. These results indicate that HVEM may be a novel therapeutic target for inflammation-induced negative energy balance.

METHODS

Animal care and treatment

Eight- to 10-week-old male C57BL/6 mice and mice lacking

HVEM expression (HVEM-/-) were maintained under specific pathogen-free conditions [25]. Mice were fed standard chow (Feedlab, Guri, Korea) ad libitum. Animals were housed under controlled temperature (23°C to 25°C) and a 12-hour lightdark cycle, with light from 6:00 AM to 6:00 PM. Animal experiments were conducted in accordance with the regulations of University of Ulsan for the Care and Use of Laboratory Animals (Permission No. UOU-2011-005).

Mice were IP-injected with LPS (100 µg/kg, Sigma-Aldrich, St. Louis, MO, USA) or ICV-injected with recombinant mouse LIGHT (300 ng/2 µL, Research & Diagnostics, Minneapolis, NE, USA) at 4:00 PM. Food intake and body weight were measured at 24 hours after injection of LIGHT and LPS.

Stereotaxic surgery and ICV-administration

Mice were anesthetized with an IP-injection of tribromoethanol (250 µg/mouse, Sigma-Aldrich) and were placed in a stereotaxic apparatus (Stoelting, Wood Dale, IL, USA). A polyethylene cannula was implanted into the lateral ventricle (coordinates of 0.03 mm posterior, 0.1 mm lateral, and 2.4 mm ventral to the bregma) and secured to the skull with dental cement. Mice were immediately placed in individual cages. After 1 week of recovery, test materials were injected through the cannula. Recombinant mouse LIGHT (300 ng) was injected in 2 µL total volume.

Immunohistochemistry

The mice were anesthetized with tribromoethanol and transcardially perfused with 10 mL ice-cold 0.1 M phosphate buffer (PB, pH 7.4), followed by 10 mL 4% paraformaldehyde. The brains were dissected and postfixed overnight in the same fixative containing 20% sucrose. Brains were dehydrated and placed in an embedding medium (Tissue-Tek, Torrance, CA, USA), and slide-mounted sections were prepared with a cryostat. The frozen sections of brain were completely dried and washed with 0.1 M PB for 30 minutes. Sections were incubated with blocking buffer (3% nonfat milk, 0.3% Triton X-100 and 0.1 M PB). After washing the slides three times with 0.1 M PB for 5 minutes, slides were incubated with goat antimouse HVEM antibody (1:250, Santa Cruz, Billerica, MA, USA) overnight at room temperature and then washed three times with 0.1 M PB for 10 minutes. After washing, the sections were incubated with biotin-conjugated donkey antigoat IgG (1:400, Vector Labs, Burlingame, CA, USA) in PB for 2 hours. Staining was performed using an ABC kit (Vector Labs), color development was achieved by incubating the sections for 5 minutes with the tyramide signal amplification system (NEN Life Science, Boston, MA, USA), and images were obtained using fluorescence microscopy.

Statistical analyses

All results are expressed as mean \pm standard error of measure (n are given in the figure legends). Statistical analyses were performed using repeated measures analysis of variance with Bonferroni $post\ hoc$ analyses. A two-tailed unpaired Student t test was used for comparison between two groups.

RESULTS

In order to assess role of LPS in energy homeostasis, mice were injected with LPS into the abdominal cavity. Administration of LPS significantly decreased food intake, measured for 24 hours after the injection of LPS (Fig. 1A). This anorectic effect of LPS resulted in a decrease of body weight over the 24 hours duration (Fig. 1B). Control saline-injected animals showed an average of 0.1 g of weight loss over the 24 hours, while LPS-injected mice lost an average of 2.78 g. These results suggest that the administration of LPS decreased food intake, thereby reducing body weight.


We next assessed if LPS induced change in the hypothalamic expression of HVEM using immunohistochemistry. IP-injection of LPS strongly increased the HVEM immunoreactivity in the hypothalamic arcuate nucleus (ARC) (Fig. 2), suggesting that the LPS-induced inflammation affects HVEM expression in the ARC.

Because LPS increased the expression of HVEM in the ARC, we hypothesized that HVEM signaling might be required for the LPS-induced anorexia and body weight loss. To investigate the role of HVEM during the LPS-induced anorexia and body weight loss, the HVEM-/- mice were injected with LPS and food intake and body weight were measured. As already shown in Fig. 1, the wild-type mice exhibited a decreased food intake and body weight following the IP administration of LPS (Fig. 3). However, LPS induced only a minor decrease in food intake and body weight in the HVEM-/- mice (Fig. 3). These results suggest that the HVEM signaling plays a pivotal role in the LPS-induced anorexia and body weight loss.

The interaction of HVEM with its ligand LIGHT has been known to promote inflammatory responses and the subsequent production of proinflammatory cytokines [26]. Thus, we examined the effect of LIGHT on the anorexia and body weight loss. Mice were ICV-injected into the lateral ventricle with recombinant LIGHT. The ICV administration of LIGHT significantly decreased food intake and body weight in the wild-type mice for 24 hours (Fig. 4). However, the same administration caused a significantly smaller decrease in food intake and body weight in the HVEM-/- mice during the same observation period (Fig. 4). These results suggest that the interaction of LIGHT with HVEM in the brain plays an essential role in the regulation of food intake and body weight.

DISCUSSION

Reduced appetite is a hallmark of the inflammatory diseases






Fig. 1. Effect of lipopolysaccharide (LPS) on food intake and body weight. Food intake and body weight were measured in mice that had received an intraperitoneal administration of LPS. (A) Food intake was measured for 24 hours after administration of LPS (100 μg/kg). Control mice (CTL) received 0.9% saline solution. (B) Effect of LPS on body weight changes 24 hours after administration of LPS. Data are represented as mean±standard error of measure (n=4). ^{a}P <0.001 vs. control mice.




Fig. 2. Effect of lipopolysaccharide (LPS) on herpes virus entry mediator (HVEM) expression in the hypothalamic arcuate nucleus. LPS (100 μ g/kg) was intraperitoneally-injected into the mice. Three hours after the injection, the mice were sacrificed and their brains were fixed via transcardiac perfusion. HVEM expression was determined using immunohistochemistry. (A, B) The panels show representative results from two repeated experiments using mice injected with (A) control or (B) LPS. (C) An amplification image (×200) of the inset of panel (B, ×100). Scale bar=100 μ m. 3V, third ventricle; CTL, control mice injected with 0.9% saline solution.





Fig. 3. Herpes virus entry mediator (HVEM) signaling is required for lipopolysaccharide (LPS)-induced anorexia. Food intake and body weight were measured in mice that received an intraperitoneal-injection of LPS (100 μ g/kg). (A) Effect of LPS on the change in food intake in the HVEM-/- mice. Food intake was measured for 24 hours after administration of LPS. Control mice (CTL) received 0.9% saline solution. (B) Effect of LPS on body weight changes for 24 hours. Data are represented as mean \pm standard error of measure (n=4). a P<0.001 vs. control mice; b P<0.01 vs. LPS-injected wild-type mice.

[1-3,27] and is concomitant with many chronic pathological conditions, including cancer. This negative energy balance is controlled by the proinflammatory cytokines in the brain [10,11]. Members of the TNFRSF play a key role in regulating immune

responses to infection [16]. HVEM, a member of TNFRSF, activates transcription factors, such as NF-κB and AP-1 [20], which control the expression of genes involved in multiple immune, inflammatory, and acute-phase responses to infection






Fig. 4. Effect of LIGHT on the food intake and body weight of herpes virus entry mediator (HVEM)-/- mice. Food intake and body weight were measured in mice which received an intracerebroventricular (ICV) administration of LIGHT (300 ng). (A) Effect of ICV-injected LIGHT on the change in food intake in HVEM-/- mice. Food intake was measured for 24 hours after administration of LIGHT. Control mice (CTL) received 0.9% saline solution. (B) Effect of LIGHT on body weight change for 24 hours after the ICV-injection of LIGHT. Data are represented as mean \pm standard error of measure (n=4). aP <0.001 vs. control mice; bP <0.05 vs. LIGHT-injected wild-type mice.

[28]. Recent studies have demonstrated that HVEM signaling plays a critical role in promoting proinflammatory cytokine production in peripheral tissues, where cytokines are involved in intestinal inflammation, hepatitis, and diet-induced obesity [21-23].

In this study, we demonstrated that the HVEM signaling in the brain contributes to acute inflammation-induced anorexia and weight loss. At the beginning of this study, we found that severe anorexia and body weight loss was induced in mice suffering from intestinal inflammation caused by the administration of dextran sulfate sodium (data not shown). However, we found that the HVEM-/- mice showed attenuated intestinal inflammation and body weight loss (data not shown), as previously reported [21]. Therefore, the attenuated inflammation in HVEM-/- mice might contribute to the amelioration of anorexia. This study together with the previous report [21] indicates that the HVEM signaling is necessary for the intestinal inflammation-induced anorexia and body weight loss.

LPS is a representative bacterial endotoxin for the simulation of acute bacterial infection and inflammation. In this study, we found that administration of LPS significantly reduced food intake as well as body weight, and moreover, increased the expression of HVEM in the hypothalamic ARC. It has been reported that IP-injection of LPS strongly increased serum levels of proinflammatory cytokines, which affect the hypothalamic

center for energy homeostasis [29]. The hypothalamus plays a crucial role in the control of feeding behavior and energy expenditure [30,31]. Numerous inflammatory stimuli activate the hypothalamic proinflammatory cytokines, such as tumor necrosis factor- α , interleukin-1 β (IL-1 β), and IL-6, which are involved in the sickness behavior characterized by anorexia and fever [32].

It is likely that the LPS-induced activation of hypothalamic HVEM signaling plays an important role in activating proinflammatory cytokines, subsequently resulting in the decreases of food intake and body weight. Indeed, loss of HVEM expression in the HVEM-/- mice (and thus, loss of the activation of its signaling) gave rise to the improvement from the LPS-induced anorexia and body weight loss. Peripheral inflammatory mediators stimulated by LPS may exert brain responses via HVEM signaling. Indeed, peripheral administration of LPS was shown to activate production of inflammatory cytokines that cause neuroinflammatory responses in the brain, particularly in the microglia and astrocytes [33]. HVEM might be induced in the microglia and astrocytes during this neuroinflammatory process as shown in this study.

To address whether the activation of brain HVEM is responsible for inflammation-induced negative energy balance, changes in food intake and body weight were measured in mice received LIGHT, a stimulatory ligand of HVEM, in their brain.

ICV-administration of LIGHT significantly decreased food intake in the wild-type mice, suggesting that the activation of brain HVEM is a plausible cause of the inflammation-induced negative energy balance. Moreover, the ICV-injection of LIGHT was less effective in decreasing food intake and body weight in the HVEM-/- mice, further indicating that the activation of brain HVEM by LIGHT (or other inflammatory stimuli) is responsible for the negative energy balance. However, LIGHTinduced decreases in food intake and body weight were not completely suppressed in the HVEM-/- mice, likely owing to the fact that LIGHT can exert its effects through other receptors, such as the lymphotoxin β receptor [34].

Taken together, this study suggests that HVEM signaling in the brain plays an important role in regulating energy homeostasis by activating inflammation-induced anorexia and body weight loss and that HVEM is a good candidate for a therapeutic target to improve quality of life for inflammatory disease patients.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This study was supported by a grant (A121673) from the Korea Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.

REFERENCES

- 1. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988;12:123-37.
- 2. Plata-Salaman CR. Anorexia during acute and chronic disease. Nutrition 1996;12:69-78.
- 3. Szelenyi Z, Szekely M. Sickness behavior in fever and hypothermia. Front Biosci 2004;9:2447-56.
- 4. Matthys P, Billiau A. Cytokines and cachexia. Nutrition 1997;13:763-70.
- 5. Kotler DP. Cachexia. Ann Intern Med 2000;133:622-34.
- 6. Grinspoon S, Mulligan K; Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis 2003;36(Suppl 2):S69-78.

- 7. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999;19:223-48.
- 8. Langhans W. Anorexia of infection: current prospects. Nutrition 2000:16:996-1005.
- 9. McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. JPEN J Parenter Enteral Nutr 1992;16(6 Suppl):50S-55S.
- 10. Harden LM, du Plessis I, Poole S, Laburn HP. Interleukin (IL)-6 and IL-1 beta act synergistically within the brain to induce sickness behavior and fever in rats. Brain Behav Immun 2008;22:838-49.
- 11. Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, Johnson RW. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 2005;19: 1329-31.
- 12. Kluger MJ. Fever: role of pyrogens and cryogens. Physiol Rev 1991;71:93-127.
- 13. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
- 14. Wohleb ES, Fenn AM, Pacenta AM, Powell ND, Sheridan JF, Godbout JP. Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice. Psychoneuroendocrinology 2012;37:1491-505.
- 15. Hines DJ, Choi HB, Hines RM, Phillips AG, MacVicar BA. Prevention of LPS-induced microglia activation, cytokine production and sickness behavior with TLR4 receptor interfering peptides. PLoS One 2013;8:e60388.
- 16. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995;85:3378-404.
- 17. Shui JW, Steinberg MW, Kronenberg M. Regulation of inflammation, autoimmunity, and infection immunity by HV-EM-BTLA signaling. J Leukoc Biol 2011;89:517-23.
- 18. Steinberg MW, Shui JW, Ware CF, Kronenberg M. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol 2009;31:207-21.
- 19. Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 2009;229:244-58.
- 20. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M,

- Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem 1997;272:14029-32.
- 21. Schaer C, Hiltbrunner S, Ernst B, Mueller C, Kurrer M, Kopf M, Harris NL. HVEM signalling promotes colitis. PLoS One 2011;6:e18495.
- 22. Wang J, Anders RA, Wang Y, Turner JR, Abraham C, Pfeffer K, Fu YX. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol 2005; 174:8173-82.
- 23. An MM, Fan KX, Cao YB, Shen H, Zhang JD, Lu L, Gao PH, Jiang YY. Lymphtoxin beta receptor-Ig protects from T-cell-mediated liver injury in mice through blocking LIGHT/ HVEM signaling. Biol Pharm Bull 2006;29:2025-30.
- 24. Kim HJ, Kim HM, Kim CS, Jeong CS, Choi HS, Kawada T, Kim BS, Yu R. HVEM-deficient mice fed a high-fat diet are protected from adipose tissue inflammation and glucose intolerance. FEBS Lett 2011:585:2285-90.
- 25. Kim WK, Park JS, Sul OJ, Seo JH, Choi BK, Park HY, Latour AM, Koller BH, Kwon BS, Jeong CS. Role of TNFRrelated 2 mediated immune responses in dextran sulfate sodium-induced inflammatory bowel disease. Mol Cells 2011;31:99-104.

- 26. Kim HM, Jeong CS, Choi HS, Kawada T, Yu R. LIGHT/ TNFSF14 enhances adipose tissue inflammatory responses through its interaction with HVEM. FEBS Lett 2011;585: 579-84.
- 27. Langhans W. Signals generating anorexia during acute illness. Proc Nutr Soc 2007;66:321-30.
- 28. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-6.
- 29. Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 2013;61:71-90.
- 30. Elmquist JK, Flier JS. Neuroscience. The fat-brain axis enters a new dimension. Science 2004;304:63-4.
- 31. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443:289-95.
- 32. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002;25:154-9.
- 33. Jeong HK, Jou I, Joe EH. Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra. Exp Mol Med 2010;42:823-32.
- 34. Ware CF. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol Rev 2008;223: 186-201.